PORTLAND, Maine, (September 13, 2023) In the first publication of its kind, a recently published study examines CBD and CBDA’s metabolism and potential drug-drug interactions involving canine cytochrome P-450 metabolism, UDP-glucuronosyltransferase conjugation, and P-glycoprotein drug efflux influences.
The publication, led by Dr. Michael H. Court of Washington State University, utilized dog liver microsomes to better characterize how the liver metabolizes CBD and CBDA.
“The way in which the liver handles CBD and CBDA has long been a question since dogs do not make the typical metabolites that rats and humans make,” said paper co-author Dr. Joseph Wakshlag, DVM, PhD, DACVIM (Nutrition), DACVSMR and Chief Veterinary Medical Officer at ElleVet Sciences
The publication suggests that CBD and CBDA are each metabolized differently in dogs, with P450 enzymes, particularly CYP1A2 and CYP2C21, playing a major role with CYP1A2 being the likely primary metabolizer of CBD. The factors influencing the activity of these enzymes, such as co-administration of drugs that are enzyme inducers or inhibitors, or genetic polymorphisms, could alter the bioavailability and biological effects of these phytocannabinoids. CBDA appears to skip the first step of the biotransformation and is directly glucuronidated (the glucose-like molecule) on the carboxylic acid, which makes CBD different from CBDA.
“This publication is emblematic of ElleVet’s mission to improve the lives of animals through science,” said ElleVet Sciences CEO and Co-Founder Christian Kjaer, “Furthering our understanding of how CBD and CBDA are uniquely metabolized in dogs enables us to continuously innovate and develop CBDA-based products that improve the quality of life for dogs and their owners.”
“We now know that the CYP1 system is heavily involved in CBD metabolism and based on physiological concentrations of CBD and CBDA observed in dogs. Pharmacodynamic modeling suggests minimal risk of significant interactions with other concomitantly used drugs at current administration recommendations. Most importantly, CBD and CBDA does not alter activity of the multi-drug resistant transporter showing that it should be safe for all dogs,” said Dr. Wakshlag.
About Ellevet Sciences
ElleVet Sciences is a leading science-driven animal health company headquartered in South Portland, Maine. As the first organization to conduct successful clinical trials on the safety and efficacy of CBD + CBDA for pets, ElleVet continues to lead the field through research and innovation in collaboration with top veterinary professionals and institutions. The company has pioneered and patented safe, effective products for dogs, cats, and horses, offering support for mobility, stress, skin health, and brain function. Carried by thousands of veterinary clinics across the US, ElleVet is committed to improving the lives of companion animals, with both heart and science at the core of its mission.